Pfizer Inc (NYSE: PFE)

Last Updated: Sep-27-2016 23:54:40

PFE News & Stock Updates

Click here to read more stories
  • Pfizer (NYSE: PFE) Stock Price Predictions Look Bullish After $160 Billion Merger

    Pfizer Inc. (NYSE: PFE) and competitor Allergan Plc. (NYSE: AGN) announced the largest healthcare deal in history today (Monday).

    The combination is a very bullish catalyst for the PFE stock price.

    Here's why...
  • Pfizer Stock Price Will Climb After Merger Despite U.S. Treasury Efforts

    The Pfizer stock price is up 0.5% today as the U.S. drug giant remains in advanced stages to buy Allergan Plc. (NYSE: AGN).

    Pfizer Inc. (NYSE: PFE) is pushing forward with the deal despite the best wishes of the U.S. Treasury, which is trying to curb such mergers.

    Here's why...
  • Pfizer Inc. (NYSE: PFE) Reports Strong Quarterly Profits

    7/28/15 PFE: Shares of Pfizer Inc. (NYSE: PFE) gained more than 1% after it reported stronger than expected adjusted quarterly profits. But the bigger news was the firm's 7% decline in its quarterly revenue figures. The company's global profits were affected by a strong U.S. dollar.

  • Merck, Pfizer Earnings Send Shares in Opposite Directions (NYSE: PFE) (NYSE: MRK)

    The Pfizer earnings and Merck earnings reports were both released this morning (Tuesday), and investors are acting differently to these major pharmaceutical stocks.

    Pfizer Inc. (NYSE: PFE) stock was up 1.3% in early trading despite missing earnings per share estimates. Merck shares were down 2% despite topping estimates.

    Here's why the stocks are behaving so differently...
  • Pfizer Inc. (NYSE: PFE) Favored by Jeffries

    5/21/2015: Pharmaceutical giant Pfizer Inc. (NYSE: PFE) is in focus after it received a heap of praise from one of Wall Street's most prominent banks, Jefferies. The firm said Pfizer is its top global pharmaceutical stock to own. PFE made our list of most profitable pharmaceutical companies this year, with pharma revenue near $45 billion […]

  • Pfizer Inc. (NYSE: PFE) Makes Most-Profitable Pharma List

    5/14/2015: Pfizer Inc. (NYSE: PFE) made our list of most profitable pharmaceutical companies this year, with pharma revenue near $45 billion annually. Pfizer’s diabetes treatment Lyrica is the company’s biggest revenue generator as it brought in $5.1 billion in 2014. The pharmaceutical industry is one of the most profitable sectors in the world. More than […]

  • Pfizer (NYSE: PFE) Halts Vaccine Sales in China

    4/3/15: Pfizer Inc. (NYSE: PFE) is ceasing vaccine sales operations in China after the Chinese government failed to renew an import license for one of its products, a move that the company said will cause a shortage of the treatment in China. The vaccine protects toddlers against pneumococcal disease that can lead to pneumonia and […]

  • Pfizer Inc. (NYSE: PFE) Bolstered by a Strong R&D Pipeline

    Pfizer Inc. (NYSE: PFE) has seen its earnings and revenue plummet during the last several years thanks to generic drugmakers invading the market with their lower priced alternatives and a number of large acquisitions over the past few years. Drugs that are currently in phase 3 trials should provide a kick to PFE earnings. Pfizer […]

  • Positive Test Results for Pfizer Inc. (NYSE: PFE) Vaccine

    3/19/15: Pfizer Inc. (NYSE: PFE) announced that the results from the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA), conducted to evaluate its best-selling vaccine Prevenar 13, have been published in the March issue of the New England Journal of Medicine. Pfizer announced that the vaccine met both primary and secondary endpoints specified for the study […]

  • Merger Mania: (NYSE: PFE) and (NYSE: HSP)

    Pharmaceutical giant Pfizer Inc. (NYSE: PFE) announced plans to purchase Hospira, Inc. (NYSE: HSP) in a deal worth $17 billion, or $90 per share. The acquisition will give Pfizer access to Hospira's bio-similars (officially approved subsequent versions of innovative drugs). The $90 per-share offer is a 39% premium to the target's stock at the close […]

  • Earnings Losers: (NYSE: PFE), (NYSE: DD), (NYSE:BMY), (NYSE: PG), (NYSE: CAT)

    Yesterday was a rough day for earnings reports. Shares of Pfizer Inc. (NYSE: PFE) slipped 0.6% today on news the company slashed its 2015 guidance during its lackluster earnings report. E.I. DuPont De Nemours and Co. (NYSE: DD) slipped 1.25% after the company offered a weak 2015 outlook and took a hit on earnings thanks to a stronger dollar. Bristol-Myers Squibb Co. (NYSE:BMY) […]

  • S&P 500 Hits New Record High on Fresh Round of Deals

    The S&P 500 eked out a 1.5-point gain Monday to strike yet another record high as a fresh round of mergers and acquisitions fueled optimism in the markets.

    Here's today's scorecard, as well as the top stories from the stock market today...
  • Striking a Deal: (NYSE: PFE), (NYSE: MRK), (NYSE ADR: AZN)

    Striking a Deal: Healthcare giant Pfizer Inc. (NYSE: PFE) announced a plan to manufacture cancer drugs with German rival Merck & Co. Inc. (NYSE: MRK). According to terms of the deal, Pfizer will pay an upfront fee to Merck worth $850 million. The deal could see Merck earn another $2 billion as the companies' efforts […]

  • Mum on Mergers: (NYSE: PFE) and (NYSE ADR: AZN)

    Shares of Pfizer Inc. (NYSE: PFE) were up more than 1% this morning on news that the company bested third-quarter earnings expectations. The pharmaceutical giant reported per-share earnings of $0.42, beating analyst estimates by $0.03. The company cited growth in sales of its cancer treatments and cited increased demand in emerging markets. However, the company […]

  • Merger Mania: (NYSE: PFE) and (NYSE: ACT)

    The Wall Street Journal reports that Pfizer Plc (NYSE: PFE) had approached Irish drug maker Actavis Plc (NYSE: ACT) recently about a proposed takeover that would have allowed the U.S. firm to re-domicile in Europe and lower its tax bill. However, the talks have broken down. Given the new rules revealed this week by the U.S. Department of Treasury, any inversions moving forward […]

  • Trouble Ahead for (NYSE: PFE) Stock

    Pfizer stock (NYSE: PFE) will soon feel the pressure from the wave of lawsuits being filed claiming that Pfizer's blockbuster drug Lipitor – the world's best-selling drug of all time – causes type-2 diabetes in women. With a market cap of more than $180 billion, the world's largest pharmaceutical firm's pockets run deep. Lipitor alone brought in […]

  • Trouble Ahead for Pfizer Stock (NYSE: PFE) as Lipitor Claims Inevitably Amass

    Updated August 14, 2014: Pfizer stock (NYSE: PFE) will soon feel the pressure from the wave of lawsuits being filed claiming that Pfizer's blockbuster drug Lipitor – the world's best-selling drug of all time – causes type-2 diabetes in women.

    "This will be a huge overhang on Pfizer stock," Money Morning Capital Wave Strategist Shah Gilani said. "Investors have to watch developments closely."

    With a market cap of more than $180 billion, the world's largest pharmaceutical firm's pockets run deep. Lipitor alone brought in global sales of more than $125 billion for Pfizer over the 14-and-a-half years since its 1996 market debut (Pfizer's patent on Lipitor expired on November 30, 2011). More than 29 million patients took the drug just in the United States.

    Here’s why there’s a recent spike in claims, and how Gilani recommends playing PFE stock in coming months…
  • Drug Problem

    Shares of pharmaceutical giant Pfizer Inc. (NYSE: PFE) are on the decline in pre-market hours on news that the company is confronting a wave of lawsuits from women over possible side effects from its anti-cholesterol drug Lipitor. According to multiple reports, the the drug may give women type-2 diabetes at a rate of 5.6 per […]

  • AMZN, BBRY, FDX Among Hot Stocks on the Move Today

    Today's hot stocks: While the FOMC meeting took center stage on Wall Street today, a number of stocks moved on earnings, company developments, and analysts' actions.

    Featured on Wednesday's hot stocks to watch list is an economic bellwether hitting an all-time high, a biopharmaceutical company surging on a promising treatment for lung infections, and a biopharma skyrocketing in its IPO.

    Check out 12 of Wednesday's movers - including AMZN, BBRY, and FDX - and find out what's behind their action...
  • Time to Profit (Again) from the "ASCO Effect"

    The American Society of Clinical Oncology meets every spring. It's attended by some 30,000 people and hosts 4,000 presentations.

    Investors like us love ASCO because of the so-called "ASCO Effect" – a hefty surge in cancer-focused biotech stocks that always accompanies the start of this meeting.

    And we usually recommend an oncology stock or two ourselves.

    This year's ASCO turned us on to an important new trend – one that's shaping up as the next big profit opportunity in biotech.

    Full Story

Premium Research

Pfizer Inc (NYSE: PFE) Profile

Prior Close$33.64
Market Cap$205.17 B
PE Ratio14.04
Pfizer Inc. is a research-based global pharmaceutical company that discovers develops manufactures and markets medicines for humans and animals. The Company's diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines as well as nutritional products and consumer healthcare products. Pfizer's Animal Health business unit discovers develops and sells products for the prevention and treatment of diseases in livestock and companion animals. It sells its products to wholesalers distributors retailers hospitals clinics government agencies pharmacies individual provider offices veterinarians livestock producers and grocery and convenience stores. Pfizer Inc. is headquartered in New York.
SymbolCompanyMarket cap
JNJJohnson & Johnson$325.05 B
RHHBYRoche Hldg Ltd Spons$215.03 B
NVSNovartis Ag$194.02 B
MRKMerck & Company$174.1 B
NVONovo Nordisk A/S$113.43 B
GSKGlaxosmithkline Plc$105.85 B
ABBVAbbvie Inc Common Stock$105.82 B
SNYSanofi-Aventis Sa$98.72 B
BMYBristol-Myers Squibb Company$94.37 B
LLYEli Lilly and Company$89.59 B

PFE Earnings

1st Quarter Earnings$0.64 (2016-08-02)
2nd Quarter Earnings$0.67 (2016-05-03)
3rd Quarter Earnings$0.53 (2016-02-02)
4th Quarter Earnings$0.6 (2015-10-27)
PE Ratio14.04
EPS Growth11.77%
Recent Earnings$0.64
Annual EPS$2.44
Market Capitalization$205.17 B
Insider Shareholder %0.0007%
Annual Revenue$52.29 B
Number of Shares Outstanding6,064,850 Shares
Institutional Shareholder %69.65%
Annual Net Income$7.78B
TTM Net Profit Margin$13.38
One Year Return13.05%
Three Year Return25.89%
Five Year Return123.02%
Five Year Revenue Growth-27.96%
Five Year Earnings Growth-1.35%
Five Year Dividend Growth55.56%
Last Quarter EPS$0.64
Annual EPS$2.44
Annual Dividend$1.2
Annual Dividend Yield3.5%
Change in EPS YTD11.77%
PE Ratio14.04
Recent Earnings$0.64
Dividends per Share$0.3
Stock Split Ratio3-1

PFE Key Stats

Last Price$33.83
Net Change$0.19 (0.56%)
Ask Price$0
Open Price$33.78
Previous Close Price$33.64
High Price$33.88
Low Price$33.48
Number of Trades53,818
Fifty Two Week High$37.39 (2016-08-01)
Fifty Two Week Low$28.25 (2016-02-08)
Average Daily Volume33,043,703
Share Outstanding6,064,850 Shares
Total Dividend Payout$1.2/yr
Dividend Yield3.5%